RCM
EW icon

Riverhead Capital Management’s Edwards Lifesciences EW Stock Holding History

Riverhead Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2.77M Buy
37,785
+6,537
+21% +$459K 0.1% 257
2019
Q2 		$1.92M Buy
31,248
+5,325
+21% +$322K 0.07% 348
2019
Q1 		$1.65M Buy
25,923
+1,776
+7% +$101K 0.07% 359
2018
Q4 		$1.23M Buy
24,147
+2,223
+10% +$112K 0.06% 390
2018
Q3 		$1.27M Sell
21,924
-240
-1% -$11.7K 0.05% 425
2018
Q2 		$1.08M Buy
22,164
+1,695
+8% +$79.1K 0.04% 446
2018
Q1 		$952K Sell
20,469
-2,196
-10% -$95.4K 0.04% 442
2017
Q4 		$851K Buy
22,665
+2,730
+14% +$100K 0.04% 476
2017
Q3 		$726K Sell
19,935
-10,587
-35% -$404K 0.03% 487
2017
Q2 		$1.2M Sell
30,522
-15,528
-34% -$567K 0.06% 347
2017
Q1 		$1.44M Sell
46,050
-91,281
-66% -$2.86M 0.08% 299
2016
Q4 		$4.29M Sell
137,331
-600
-0.4% -$19.4K 0.26% 100
2016
Q3 		$5.54M Buy
137,931
+105,096
+320% +$3.96M 0.36% 64
2016
Q2 		$50K Sell
32,835
-749,652
-96% -$25.6M ﹤0.01% 1325
2016
Q1 		$23M Buy
782,487
+182,559
+30% +$5.04M 0.32% 74
2015
Q4 		$15.8M Buy
599,928
+288,654
+93% +$7.5M 0.23% 110
2015
Q3 		$7.38M Buy
311,274
+24,936
+9% +$602K 0.12% 244
2015
Q2 		$6.8M Buy
286,338
+4,836
+2% +$109K 0.1% 268
2015
Q1 		$6.68M Sell
281,502
-1,344
-0.5% -$30.2K 0.1% 265
2014
Q4 		$6.01M Buy
282,846
+137,838
+95% +$2.77M 0.09% 275
2014
Q3 		$2.47M Buy
145,008
+51,252
+55% +$809K 0.04% 417
2014
Q2 		$1.34M Buy
93,756
+10,608
+13% +$144K 0.03% 505
2014
Q1 		$1.03M Buy
83,148
+5,886
+8% +$67.9K 0.02% 503
2013
Q4 		$847K Buy
77,262
+41,262
+115% +$465K 0.02% 466
2013
Q3 		$418K Hold
36,000
– – 0.01% 419
2013
Q2 		$403K Buy
+36,000
New +$426K 0.01% 435

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Riverhead Capital Management's EW Position: Q3 2019 in Review

Riverhead Capital Management increased its Edwards Lifesciences (EW) stake by 21% in Q3 2019, buying an estimated $459K and bringing the position to 37,785 shares worth $2.77M. The position accounts for 0.1% of the portfolio, ranked #257.

Riverhead Capital Management first reported a position in EW in Q2 2013 and has held it in 26 quarters since. The position peaked at $23M in Q1 2016. 965 funds tracked by Wall St. Rank hold EW as of Q3 2019.

  • Riverhead Capital Management held 37,785 shares of Edwards Lifesciences worth $2.77M as of Q3 2019.
  • Riverhead Capital Management bought 6,537 Edwards Lifesciences shares in Q3 2019, an estimated $459K.
  • Edwards Lifesciences made up 0.1% of Riverhead Capital Management's portfolio in Q3 2019, its #257 holding.
  • Riverhead Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 26 quarters since.
  • Riverhead Capital Management's Edwards Lifesciences position peaked at $23M in Q1 2016.
  • 965 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.